Biomarker Strategies: Greg Bertenshaw
Biomarker Strategies has promoted Greg Bertenshaw to the position of chief operating and science officer. Bertenshaw was formerly vice president of R&D and director of R&D for the company, which he joined in 2011 as a senior scientist. Bertenshaw has also previously served as director of new technology for Correlogic Systems, and as a scientist and director of science for Clearant. He holds a PhD in biochemistry and molecular biology from Penn State University College of Medicine.
NeoGenomics: Rachel Stahler
NeoGenomics announced Rachel Stahler would join the company's board of directors, effective immediately. She will serve on the board's audit committee. Stahler was recently named the chief information officer for Merck's intended women's health and biosimilars spinoff Organon & Co. Previously, she was the CIO at pharmaceuticals firm Allergan, Syneos Health, and Optimer Pharmaceuticals.
Oxford Biodynamics: Peter Pack
Oxford BioDynamics has appointed Peter Pack as independent non-executive chairman of the firm. He will be replacing Stephen Diggle, who will transition to the role of non-executive director. Prior to joining the firm's board in 2019 as non-executive director, Pack headed Crescendo Biologics from 2015 to 2019. Pack also served as cofounder and CEO of MTM laboratories prior to its acquisition by Roche Diagnostics. Before launching MTM laboratories, Pack began his career at MorphoSys.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.